Recursion Pharmaceuticals continues to have a pipeline of drugs that might provide further validation for the company's platform. See why I rate RXRX a Sell.

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. | Recursion is ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across ...

Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (NASDAQ: RXRX). The company has emerged as a ...

NVIDIA's continued investment in Recursion Pharmaceuticals strengthens the view that Recursion is a favored investment within NVIDIA's AI portfolio, especially in the fledgling AI biotech sector ...

If policymakers fail to act swiftly to restore medical research funding, then it’s up to those of us in the industry with the resources to bridge the gap, writes Recursion Pharmaceuticals CEO ...

Is Recursion Pharmaceuticals stock a buy? Does any of this change the premise for buying Recursion Pharmaceuticals stock? Not really. The company's technology is promising.

Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (NASDAQ: RXRX) could be positioned to ride the ongoing wave of ...

Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger Recursion is working on 10 potential drugs, and has enough cash to fuel itself through 2027 Adobe ...